Key facts
- Active ingredient: tirzepatide, a 39-amino-acid synthetic peptide with a fatty-acid chain for once-weekly dosing.
- Class / mechanism: dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — the first of its kind.
- Developer: Eli Lilly and Company (compound code LY3298176).
- Approval status: FDA-approved for type 2 diabetes in May 2022; also authorized in the EU, UK, Japan, Australia and Canada. In the US the same molecule is sold as Zepbound for weight management; in the UK and EU the Mounjaro brand covers both indications.
- Route: once-weekly subcutaneous injection (single-dose pen or vial). No oral form exists.
- Evidence level: strong. Phase 3 SURPASS program in type 2 diabetes, SURMOUNT program in obesity, and a dedicated cardiovascular outcomes trial with more than 13,000 participants.
- Commonly reported side effects: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia — mostly mild to moderate and concentrated during dose escalation.
- Legal status: prescription-only medicine in every market where it is approved. Not a supplement, not available over the counter.
What is Mounjaro?
Mounjaro is the trade name Eli Lilly uses for tirzepatide in its type 2 diabetes indication. One molecule, one weekly injection, two receptor targets.
Tirzepatide is a synthetic 39-amino-acid peptide built on the backbone of native GIP, modified so that it also binds the GLP-1 receptor and carrying a C20 fatty diacid chain that binds albumin and stretches its half-life to roughly five days — which is what makes once-weekly injection practical. It belongs to the same engineering lineage as the rest of the GLP-1 receptor agonist class, but it is the first marketed drug to hit two incretin receptors at once.
The brand name matters because the same compound is sold under different labels. In the United States, Mounjaro is licensed for type 2 diabetes and Zepbound is the obesity brand. In the UK and EU there is no Zepbound — Mounjaro carries both indications. For molecule-level detail rather than the brand view, see the tirzepatide research page.
How does Mounjaro work?
Food entering the small intestine triggers release of two incretin hormones: GIP from K cells in the duodenum and GLP-1 from L cells further downstream. Both amplify insulin secretion in a glucose-dependent way, which is why incretin-based drugs rarely cause hypoglycemia on their own. GLP-1 additionally suppresses glucagon, slows gastric emptying, and acts on hypothalamic circuits that regulate appetite and satiety — the physiology is well characterized in the classic review of GLP-1 physiology and in more recent work on peptide hormones in appetite regulation.
Semaglutide, dulaglutide and liraglutide engage only the GLP-1 receptor. Tirzepatide engages both, and it does so unevenly. Receptor pharmacology work published in JCI Insight showed tirzepatide behaves as an imbalanced and biased dual agonist: it mimics native GIP closely at the GIP receptor, but at the GLP-1 receptor it favors cAMP signaling over beta-arrestin recruitment and triggers less receptor internalization than GLP-1 itself.
Adding GIP agonism appears to improve insulin secretion and insulin sensitivity, and there is evidence it also acts on adipose tissue and on brain GIP receptors involved in nausea signaling — possibly part of why tirzepatide delivers more weight loss without a proportionally worse gastrointestinal profile. That mechanistic difference is the biggest reason Mounjaro and Ozempic behave differently head to head.
Is Mounjaro FDA approved?
Yes — for type 2 diabetes. The FDA approved Mounjaro on 13 May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It was the first dual GIP/GLP-1 receptor agonist ever approved. European authorization followed in September 2022, and Japan, the UK, Canada and Australia have all since licensed it.
Where it gets confusing is weight management, because Lilly took different regulatory routes in different regions:
- United States: Mounjaro is approved only for type 2 diabetes. Tirzepatide for chronic weight management was approved separately in November 2023 under the brand Zepbound, which added an obstructive sleep apnea indication in December 2024.
- United Kingdom: the MHRA authorized Mounjaro for weight management in November 2023, so a single brand covers both diabetes and obesity. There is no Zepbound in the UK.
- European Union: the EMA label for Mounjaro likewise covers both type 2 diabetes and weight management.
In every one of those markets Mounjaro is prescription-only. It is not a supplement and it is not legally sold direct to consumers. Compounded tirzepatide proliferated in the US while the product was in shortage; the FDA declared that shortage resolved in December 2024, which removed the basis for large-scale compounding. Anything sold as "research grade" tirzepatide sits outside the regulated supply chain entirely — see the legal status of peptides for how those categories differ.
Does Mounjaro actually work? The SURPASS trials
The SURPASS program is unusually strong by diabetes-drug standards: five global phase 3 trials that tested tirzepatide against placebo, against the best-in-class GLP-1 agonist, and against two different insulins. The results were consistent across all of them.
SURPASS-1 tested tirzepatide as monotherapy in 478 participants over 40 weeks. Mean HbA1c fell 1.87 to 2.07 percentage points depending on the study dose, versus a 0.04-point rise on placebo, and 87 to 92 percent of treated participants reached an HbA1c below 7.0 percent compared with 20 percent on placebo. No severe hypoglycemia occurred in the tirzepatide arms.
SURPASS-3 and SURPASS-4 compared it against insulin. Against once-daily insulin degludec over 52 weeks, tirzepatide cut HbA1c by 1.93 to 2.37 points versus 1.34 for insulin, and participants lost 7.5 to 12.9 kg while the insulin group gained 2.3 kg. Against insulin glargine in people at elevated cardiovascular risk, hypoglycemia occurred in 6 to 9 percent of tirzepatide participants versus 19 percent on glargine.
| Trial | Comparator | Duration | HbA1c change, tirzepatide | HbA1c change, comparator | Body weight |
|---|---|---|---|---|---|
| SURPASS-1 | Placebo | 40 weeks | −1.87% to −2.07% | +0.04% | −7.0 to −9.5 kg |
| SURPASS-2 | Semaglutide 1 mg | 40 weeks | −2.01% to −2.30% | −1.86% | 1.9–5.5 kg more than semaglutide |
| SURPASS-3 | Insulin degludec | 52 weeks | −1.93% to −2.37% | −1.34% | −7.5 to −12.9 kg vs +2.3 kg |
| SURPASS-4 | Insulin glargine | 52 weeks | −2.43% to −2.58% (10/15 mg) | −1.44% | Reduced vs increased on glargine |
Trials reported study doses of 5, 10 and 15 mg weekly reached after a stepwise escalation. Those are the amounts investigators administered under supervision, not a recommendation — prescribing decisions belong to a clinician.
Mounjaro and weight loss: the SURMOUNT results
SURMOUNT is the obesity program, and it is the evidence base behind the Zepbound label in the US and the Mounjaro weight-management license in the UK and EU.
SURMOUNT-1 — 72 weeks, adults with obesity without diabetes
2,539 participants. Mean weight reduction was 15.0%, 19.5% and 20.9% across the three study doses versus 3.1% on placebo. The weight curves had not fully plateaued at week 72.
SURMOUNT-2 — 72 weeks, adults with obesity and type 2 diabetes
Weight loss is consistently smaller when type 2 diabetes is present. Mean reductions were 12.8% and 14.7% versus 3.2% on placebo.
SURMOUNT-4 — what happens when you stop
After a 36-week lead-in during which participants lost 20.9% of body weight, they were randomized to continue or switch to placebo. Over the next 52 weeks the placebo group regained 14.0% while the continued group lost a further 5.5%.
SURMOUNT-OSA — obstructive sleep apnea
In adults with moderate-to-severe OSA and obesity, tirzepatide cut the apnea-hypopnea index by 25 to 29 events per hour versus about 5 on placebo — the basis for the sleep apnea indication.
The SURMOUNT-4 finding is the one people underestimate. Stopping treatment reverses most of the benefit, which is also what happened after semaglutide withdrawal in the STEP 1 extension. Obesity is being treated here as a chronic relapsing condition, not a course of therapy with an end date. If you are comparing options across the class, our overview of peptides studied for weight loss sets the trial results side by side.
Mounjaro vs Ozempic: what the head-to-head data show
This is the comparison everyone searches for, and unusually there is real randomized evidence rather than cross-trial guesswork.
SURPASS-2 randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks. All three tirzepatide doses beat semaglutide: HbA1c fell 2.01 to 2.30 points versus 1.86, and weight fell an additional 1.9 to 5.5 kg. Gastrointestinal side effect rates were broadly similar — nausea 17–22% on tirzepatide versus 18% on semaglutide.
SURMOUNT-5 repeated the contest in obesity without diabetes, this time against semaglutide at its full 2.4 mg weight-management dose over 72 weeks. Tirzepatide produced about 20% mean weight reduction versus about 14% for semaglutide.
Two caveats keep this honest. First, SURPASS-2 used semaglutide 1 mg, the maximum Ozempic dose approved at the time; a 2 mg dose was licensed later and was not tested in that trial. Second, "more weight loss on average" is not the same as "better for a given person" — tolerability, cost, insurance coverage, kidney and cardiovascular history all feed the decision. Broader class comparisons are summarized in a review of head-to-head GLP-1 agonist studies, and we break the two molecules down further in tirzepatide vs semaglutide.
Mounjaro side effects reported in trials
Across the SURPASS and SURMOUNT programs the safety signal is dominated by the gut. The most frequently reported events were nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain. In SURPASS-4 nausea affected 12–23% and diarrhea 13–22% of tirzepatide participants, versus 2% and 4% on insulin glargine. Most events were mild to moderate, clustered during the escalation phase, and declined once participants settled at a stable dose.
Less common but clinically important risks appear on the prescribing information rather than as high-frequency trial events: acute pancreatitis, gallbladder disease including cholelithiasis, acute kidney injury secondary to dehydration from persistent vomiting or diarrhea, hypersensitivity reactions, and worsening of diabetic retinopathy in people with pre-existing disease. Hypoglycemia is uncommon on tirzepatide alone but becomes a real risk when it is combined with insulin or a sulfonylurea.
The US label carries a boxed warning about thyroid C-cell tumors, based on findings in rodents given GLP-1 receptor agonists. Whether that translates to humans is unknown, but the warning contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Tirzepatide is also not recommended in pregnancy, and delayed gastric emptying can alter absorption of other oral medicines. These are exactly the details worth writing down and reviewing with a prescriber rather than tracking from memory.
Does Mounjaro protect the heart?
Until recently the honest answer was "we don't know yet." SURPASS-4 provided reassurance on safety — a hazard ratio of 0.74 for major adverse cardiovascular events versus insulin glargine, but from a trial not powered to prove benefit.
The dedicated answer arrived with SURPASS-CVOT, published in late 2025. More than 13,000 adults with type 2 diabetes and established atherosclerotic cardiovascular disease were randomized to tirzepatide or dulaglutide — an active comparator already shown to reduce cardiovascular events — and followed for a median of about four years. The primary composite of cardiovascular death, myocardial infarction or stroke occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide. Tirzepatide met the prespecified criterion for noninferiority but did not reach superiority.
That is a meaningful result read correctly: tirzepatide is not cardiovascularly inferior to an established GLP-1 agonist with proven benefit, and it achieves that alongside substantially greater weight and HbA1c reduction. It is not evidence that tirzepatide beats every alternative on hard cardiac endpoints.
How long does Mounjaro take to work?
Glucose responds first. In the SURPASS trials HbA1c — a 3-month average — had already separated from comparators by the earliest scheduled measurements, and the underlying glucose-dependent insulin response begins within the first weeks.
Weight is far slower. SURMOUNT-1 ran 72 weeks and mean weight curves were still trending downward at the end; SURMOUNT-4 extended observation to week 88 and participants who stayed on treatment kept losing. Trials also built in a stepwise escalation lasting several months, so early weeks are as much about tolerability as effect. Anyone expecting a defined finish line is reading the data wrong — and the withdrawal arm of SURMOUNT-4 shows what the clock does in reverse.
Mounjaro vs Zepbound: same drug, different label
Mounjaro and Zepbound contain the identical active molecule, tirzepatide, made by the same manufacturer. What differs is the approved indication, the pen design and packaging, the price and the insurance treatment. Lilly filed them separately in the US so that each brand carries its own label, its own trial evidence and its own reimbursement pathway — a common strategy in this class, and exactly the same one Novo Nordisk used to split semaglutide into Ozempic for diabetes and Wegovy for obesity.
Outside the US the split mostly does not exist. UK and EU patients receive Mounjaro for either indication. That is why online sources contradict each other on whether "Mounjaro is approved for weight loss" — the correct answer depends entirely on which regulator you are asking about.
Frequently asked questions
Is Mounjaro the same as Ozempic?
No. Mounjaro contains tirzepatide and Ozempic contains semaglutide. Both are once-weekly injections approved for type 2 diabetes, but tirzepatide activates two incretin receptors (GIP and GLP-1) while semaglutide activates GLP-1 only. In the SURPASS-2 head-to-head trial, all three tirzepatide doses produced larger HbA1c and body-weight reductions than semaglutide 1 mg over 40 weeks.
Is Mounjaro approved for weight loss?
It depends on the country. In the United States the Mounjaro brand is licensed only for type 2 diabetes, and the same molecule is sold as Zepbound for chronic weight management and obstructive sleep apnea. In the United Kingdom, the European Union and several other markets, the single Mounjaro brand covers both type 2 diabetes and weight management.
Is Mounjaro better than Ozempic for weight loss?
In direct comparisons tirzepatide produced more weight loss. SURPASS-2 found greater weight reduction than semaglutide 1 mg in people with type 2 diabetes, and SURMOUNT-5 compared tirzepatide with semaglutide 2.4 mg in adults with obesity without diabetes over 72 weeks, reporting roughly 20 percent versus 14 percent mean weight reduction. Individual results vary and only a clinician can judge suitability.
What are the most common Mounjaro side effects?
Gastrointestinal effects dominate every trial: nausea, diarrhea, decreased appetite, vomiting, constipation and dyspepsia. In SURPASS-2 nausea affected 17 to 22 percent of tirzepatide participants versus 18 percent on semaglutide. Most events were mild to moderate, clustered during dose escalation, and eased over time. Serious but uncommon risks listed in the label include pancreatitis, gallbladder disease and kidney injury from dehydration.
Do you regain weight after stopping Mounjaro?
Usually yes. SURMOUNT-4 ran a 36-week lead-in on tirzepatide, then randomized participants to continue or switch to placebo. The placebo group regained 14 percent of body weight over the next 52 weeks while the continued-treatment group lost a further 5.5 percent. The same rebound pattern was documented after semaglutide withdrawal. Obesity is treated as a chronic condition for this reason.
Does Mounjaro protect the heart?
SURPASS-CVOT enrolled more than 13,000 people with type 2 diabetes and established atherosclerotic cardiovascular disease and compared tirzepatide with dulaglutide over a median of about four years. The primary composite of cardiovascular death, heart attack or stroke occurred in 12.2 percent on tirzepatide versus 13.1 percent on dulaglutide. Tirzepatide met the criterion for noninferiority but not for superiority.
How long does Mounjaro take to work?
Glucose lowering begins within the first weeks of treatment, while weight change accumulates far more slowly. In SURMOUNT-1 the weight curves were still declining at week 72, and SURMOUNT-4 showed further loss out to week 88 in people who kept taking it. Trials also used a stepwise escalation lasting several months before participants reached the highest study doses.
Is Mounjaro available as a pill?
No. Tirzepatide is a peptide and is destroyed by digestive enzymes, so Mounjaro is supplied only as a once-weekly subcutaneous injection in single-dose pens or vials. Semaglutide has an oral tablet form (Rybelsus) that uses an absorption enhancer, but no oral tirzepatide product is approved anywhere as of mid-2026.
Is compounded tirzepatide the same as Mounjaro?
No. Mounjaro is a brand-name product manufactured by Eli Lilly and reviewed by regulators for identity, purity and potency. Compounded or research-labeled tirzepatide sold outside that system has not been through that review, and the US shortage conditions that had permitted large-scale compounding of tirzepatide were declared resolved in December 2024. Quality and concentration cannot be assumed.
Can you take Mounjaro if you do not have diabetes?
Tirzepatide has been studied in people without diabetes, most notably in SURMOUNT-1 and SURMOUNT-5, and is licensed for chronic weight management under the Zepbound brand in the United States and under Mounjaro in the United Kingdom and European Union. It remains a prescription-only medicine everywhere it is approved, and eligibility is a clinical decision.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1) — PubMed 34186022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — PubMed 34170647
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin (SURPASS-3) — PubMed 34370970
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4) — PubMed 34672967
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) — PubMed 41406444
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — PubMed 35658024
- Tirzepatide once weekly for obesity in people with type 2 diabetes (SURMOUNT-2) — PubMed 37385275
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4) — PubMed 38078870
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — PubMed 38912654
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist — PubMed 32730231
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
- Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710